IL17A and cancer: To our knowledge, however, and as mentioned above, there are no published clinical trials focused on the possible utility of IL-17A/IL-17AR-targeted MAbs in either the immunotherapy of human cancers, or as a strategy to counter development of IRAEs during ICI-based therapy.